These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26300878)

  • 1. Efflux-mediated resistance to a benzothiadiazol derivative effective against Burkholderia cenocepacia.
    Scoffone VC; Ryabova O; Makarov V; Iadarola P; Fumagalli M; Fondi M; Fani R; De Rossi E; Riccardi G; Buroni S
    Front Microbiol; 2015; 6():815. PubMed ID: 26300878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efflux pump-mediated drug resistance in Burkholderia.
    Podnecky NL; Rhodes KA; Schweizer HP
    Front Microbiol; 2015; 6():305. PubMed ID: 25926825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa.
    Dreier J; Ruggerone P
    Front Microbiol; 2015; 6():660. PubMed ID: 26217310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome.
    Guglierame P; Pasca MR; De Rossi E; Buroni S; Arrigo P; Manina G; Riccardi G
    BMC Microbiol; 2006 Jul; 6():66. PubMed ID: 16857052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition.
    Venter H; Mowla R; Ohene-Agyei T; Ma S
    Front Microbiol; 2015; 6():377. PubMed ID: 25972857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular approaches to pathogenesis study of Burkholderia cenocepacia, an important cystic fibrosis opportunistic bacterium.
    Bazzini S; Udine C; Riccardi G
    Appl Microbiol Biotechnol; 2011 Dec; 92(5):887-95. PubMed ID: 21997606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance.
    Buroni S; Pasca MR; Flannagan RS; Bazzini S; Milano A; Bertani I; Venturi V; Valvano MA; Riccardi G
    BMC Microbiol; 2009 Sep; 9():200. PubMed ID: 19761586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of 2-Thiocyanatopyridine Derivative 11026103 on
    Nunvar J; Hogan AM; Buroni S; Savina S; Makarov V; Cardona ST; Drevinek P
    Antibiotics (Basel); 2019 Sep; 8(4):. PubMed ID: 31546596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ace up their sleeve: a transcriptomic approach exposes the AceI efflux protein of Acinetobacter baumannii and reveals the drug efflux potential hidden in many microbial pathogens.
    Hassan KA; Elbourne LD; Li L; Gamage HK; Liu Q; Jackson SM; Sharples D; Kolstø AB; Henderson PJ; Paulsen IT
    Front Microbiol; 2015; 6():333. PubMed ID: 25954261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mla Pathway Plays an Essential Role in the Intrinsic Resistance of Burkholderia cepacia Complex Species to Antimicrobials and Host Innate Components.
    Bernier SP; Son S; Surette MG
    J Bacteriol; 2018 Sep; 200(18):. PubMed ID: 29986943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Architecture and roles of periplasmic adaptor proteins in tripartite efflux assemblies.
    Symmons MF; Marshall RL; Bavro VN
    Front Microbiol; 2015; 6():513. PubMed ID: 26074901
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Scoffone VC; Chiarelli LR; Trespidi G; Mentasti M; Riccardi G; Buroni S
    Front Microbiol; 2017; 8():1592. PubMed ID: 28878751
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against
    Chiarelli LR; Scoffone VC; Trespidi G; Barbieri G; Riabova O; Monakhova N; Porta A; Manina G; Riccardi G; Makarov V; Buroni S
    Front Microbiol; 2020; 11():562. PubMed ID: 32318042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation.
    McDowell A; Mahenthiralingam E; Dunbar KEA; Moore JE; Crowe M; Elborn JS
    J Med Microbiol; 2004 Jul; 53(Pt 7):663-668. PubMed ID: 15184539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against Burkholderia cenocepacia.
    Scoffone VC; Spadaro F; Udine C; Makarov V; Fondi M; Fani R; De Rossi E; Riccardi G; Buroni S
    Antimicrob Agents Chemother; 2014; 58(4):2415-7. PubMed ID: 24395233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of synergists that potentiate the action of polymyxin B against Burkholderia cenocepacia.
    Loutet SA; El-Halfawy OM; Jassem AN; López JM; Medarde AF; Speert DP; Davies JE; Valvano MA
    Int J Antimicrob Agents; 2015 Oct; 46(4):376-80. PubMed ID: 26187366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Broad-Host-Range Tailocin from Burkholderia cenocepacia.
    Yao GW; Duarte I; Le TT; Carmody L; LiPuma JJ; Young R; Gonzalez CF
    Appl Environ Microbiol; 2017 May; 83(10):. PubMed ID: 28258146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Auranofin Analogs with Antibacterial Properties against
    Maydaniuk D; Wu B; Truong D; Liyanage SH; Hogan AM; Yap ZL; Yan M; Cardona ST
    Antibiotics (Basel); 2021 Nov; 10(12):. PubMed ID: 34943654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages.
    Lamothe J; Valvano MA
    Microbiology (Reading); 2008 Dec; 154(Pt 12):3825-3834. PubMed ID: 19047750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence.
    Drevinek P; Mahenthiralingam E
    Clin Microbiol Infect; 2010 Jul; 16(7):821-30. PubMed ID: 20880411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.